Board Meeting Details

The meeting of the Board of Directors was duly convened and held on Wednesday, 07th October, 2026. The meeting commenced at 9:30 PM and concluded at 10:25 PM.

Key Decisions Approved

1. Approval of Valuation and Due Diligence Report

The Board reviewed and approved the Valuation Report and Due Diligence Report in relation to the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited, an unlisted public company (CIN: U74120MH2015PLC261024).

2. Approval of Proposed Acquisition

The Board approved the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited, subject to necessary approvals and execution of definitive agreements.

The acquisition will be executed through subscription to fresh equity shares to be issued by Meyonex Pharmaceuticals Limited to Tavexia Lifecare Limited.

Transaction Details

Target Company: Meyonex Pharmaceuticals Limited (Unlisted Public Company)

  • Industry: Pharmaceuticals
  • Date of Incorporation: 17 January 2015
  • Country of Operation: India
  • Face Value per Share: ₹10
  • Paid-up Capital: ₹20,00,00,000

Shareholding Structure Post-Allotment:

| Particulars | Equity Shares | Percentage |

| Existing paid-up equity shares of Meyonex Pharmaceuticals Limited | 1,39,98,120 | 40.00% |

| Fresh equity shares to be allotted to Tavexia Lifecare Limited | 2,09,97,180 | 60.00% |

| Total equity shares after proposed allotment | 3,49,95,300 | 100.00% |

Financial Terms:

  • Issue Price: ₹32 per equity share
  • Number of Shares: 2,09,97,180 equity shares
  • Total Consideration: ₹67,19,09,760 (Rupees Sixty-Seven Crore Nineteen Lakh Nine Thousand Seven Hundred Sixty only)
  • Payment Mode: Entirely in cash

Target Company Financials:

  • Turnover FY 2024: ₹13,32,07,500
  • Turnover FY 2025: ₹10,79,21,500
  • Turnover last 3 financial years: ₹13,99,81,200

Transaction Conditions

The acquisition is subject to:

  • Necessary statutory, regulatory, governmental, contractual and other approvals
  • Approval of shareholders of Tavexia Lifecare Limited, wherever required
  • Execution of definitive agreements
  • Fulfilment of terms and conditions contained in definitive agreements
  • Completion of applicable conditions precedent

The transaction shall be completed in one or more tranches.

Funding Arrangements

The Board approved in principle that the Company may raise funds required for financing the ₹67,19,09,760 consideration through:

  • Issue of securities including equity shares, warrants, debentures/debt securities
  • Preferential basis or Right Issue basis
  • Quantum, size, nature, type, issue price, timing, mode and other terms to be determined subsequently based on funding requirement, valuation, and market conditions

Additional Information

  • The acquisition is not related to promoter/promoter group/group companies of Tavexia Lifecare Limited
  • Does not fall within related party transactions
  • Not a slump sale
  • Promoter/promoter group/group companies have no interest in Meyonex Pharmaceuticals Limited

Authorization

The Board authorized designated representatives to undertake preliminary discussions, evaluations, preparatory actions, negotiate, finalize and execute requisite agreements and documents for implementing the above decisions.